On Friday, after-hours activity saw Minerva Neurosciences Inc. (NASDAQ: NERV) rise on the charts, up 7.45% to trade at $2.74 at the most recent check. The increase in after-hours trading, which follows the release of financial results this week, helped the stock regain its regular session loss.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
When will NERV make its quarterly results available?
On November 9, 2022, Minerva Neurosciences (NERV) will announce its financial results and business updates for the third quarter of 2022. On that day, at 8:30 a.m. Eastern Time, Minerva Neurosciences will present a webcast to go through the findings and updates.
More from NERV:
The U.S. Food and Drug Administration (FDA) recently sent NERV a letter stating that it will not accept the company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in schizophrenia patients. The FDA has advised that the business may ask for a Type A meeting to go through the specifics of the letter of refusal to file.
The FDA rejecting NERV’s NDA for roluperidone has caused the organization to express its dismay. Since there are presently no licensed medicines in the United States to address the negative symptoms of schizophrenia, NERV remains to offer a fresh and much-needed therapeutic option to aid patients and their families. Minerva Neurosciences planned to ask for a Type A meeting and anticipated carrying on its correspondence with the FDA.
Concerning Schizophrenia and Adverse Symptoms
A persistent, severe, and incapacitating form of the mental disease called schizophrenia is characterized by cognitive, perceptual, emotional, linguistic, and behavioral abnormalities. According to the World Health Organization, 20 million individuals worldwide suffer from schizophrenia. Negative symptoms can make people with schizophrenia retreat from society, lose interest in activities, or become incapable of finishing tasks or experiencing pleasure.
How is NERV attempting to change things?
According to Minerva Neurosciences (NERV), even in the absence of antipsychotic medications, there is a sizable proportion of schizophrenia patients who have moderate to severe primary negative symptoms, few positive symptoms, and a low likelihood of positive symptoms getting worse. According to NERV, there is a significant unmet medical need for therapies for this category of individuals.
